Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Pharmacodynamics and tolerability of acetyl starch as a new plasma volume expander in patients undergoing elective surgery
Autore:
Bremerich, DH; Lischke, V; Asskali, F; Forster, H; Behne, M;
Indirizzi:
Johann Wolfgang Goethe Univ Klinikum, Dept Anesthesiol & Resuscitat, Frankfurt, Germany Johann Wolfgang Goethe Univ Klinikum Frankfurt Germany ankfurt, Germany Johann Wolfgang Goethe Univ Klinikum, Dept Expt Anesthesiol, Frankfurt, Germany Johann Wolfgang Goethe Univ Klinikum Frankfurt Germany ankfurt, Germany
Titolo Testata:
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
fascicolo: 8, volume: 38, anno: 2000,
pagine: 408 - 414
SICI:
0946-1965(200008)38:8<408:PATOAS>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
6-PERCENT HYDROXYETHYL STARCH; FACTOR-VIII; COAGULATION;
Keywords:
blood; plasma substitutes; colloids; plasma volume expanders; pharmacodynamics; acetyl starch; hydroxyethyl starch;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
18
Recensione:
Indirizzi per estratti:
Indirizzo: Bremerich, DH Klinikum Johann Wolfgang Goethe Univ, Zentrum Anasthesiol & Wiederbelebung, Klin Anasthesiol Intensivmedizin & Schmerztherapi, Theodor Stern Kai 7, D-60590 Frankfurt, Germany Klinikum Johann Wolfgang Goethe Univ Theodor Stern Kai 7 Frankfurt Germany D-60590
Citazione:
D.H. Bremerich et al., "Pharmacodynamics and tolerability of acetyl starch as a new plasma volume expander in patients undergoing elective surgery", INT J CL PH, 38(8), 2000, pp. 408-414

Abstract

Objective: Acetyl starch (ACS) is a new synthetic colloid solution for plasma volume expansion and is now undergoing phase II clinical trials. We compared the pharmacodynamics and tolerability of ACS with those of hydroxyethyl starch (HES) in 32 patients (American Society of Anesthesiologists physical status I and II) undergoing elective surgery. Subjects, material and methods: In this prospective, randomized, double-blind trial patients received either 15 ml/kg ACS 6% (average molecular weight (Mw) 200,000/molar substitution (MS) 0.5) or HES 6% (Mw 200,000/ MS 0.5) i.v. up to a maximum dose of 1000 ml. Plemodynamic parameters, theologic parameters, volume effect, acid-base status as well as effects on hemostasis were studied. Results: After infusion of ACS and HES there was a similar increase in central venous pressure and mean arterial pressure in both groups. Acid-base status was notsignificantly altered after the end of the colloid infusions. After ACS infusion, plasma acetate concentration increased from 0.13 +/- 0.16 mg/dl to 2.87 +/- 1.13 mg/dl, however, after 24 h there was no significant difference in plasma acetate concentration compared to HES. The volume effect rangedfrom 104 - 116% (ACS) and from 88 - 118% (HES) of the colloid dose administered. These differences were not statistically significant. Partial thromboplastin time (aPTT) was only slightly increased after ACS infusion (from 38.6 +/- 5.7 sec to 41.4 +/- 5.1 sec), but was significantly increased afterHES infusion (from 38.7 +/- 5.7 sec to 46.1 +/- 7.0 sec). Conclusion: ACS and HES are equally effective plasma volume expanders; ACS might be a new, alternative colloid solution with fewer coagulation side-effects than HES.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/10/20 alle ore 05:56:41